Drug Trial Radar · NCT07660796
A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
256
Planned (sponsor's estimate)
Start
Jul 6, 2026
Primary completion
Oct 30, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jun 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
Conditions
- Hypertension
Interventions
HCP1803-3Drug
Test drug
HCP1803-4Drug
Test drug
RLD2001-1Drug
Control drug
RLD2001-2Drug
Control drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in sitting systolic blood pressureTime frame: Baseline, 10 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Donggguk University Ilsan Hospital
Goyang-si, Gyeonggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.